SYNCROVAX Trademark

Trademark Overview

On Tuesday, January 25, 2022, a trademark application was filed for SYNCROVAX with the United States Patent and Trademark Office. The USPTO has given the SYNCROVAX trademark a serial number of 97977395. The federal status of this trademark filing is REGISTERED as of Tuesday, March 12, 2024. This trademark is owned by Syncromune, Inc.. The SYNCROVAX trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Development of drugs and therapeutics; development of drug delivery technology
syncrovax

General Information

Serial Number97977395
Word MarkSYNCROVAX
Filing DateTuesday, January 25, 2022
Status700 - REGISTERED
Status DateTuesday, March 12, 2024
Registration Number7327468
Registration DateTuesday, March 12, 2024
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 6, 2022

Trademark Statements

Goods and ServicesDevelopment of drugs and therapeutics; development of drug delivery technology

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateMonday, January 31, 2022
Primary Code042
First Use Anywhere DateSaturday, October 31, 2020
First Use In Commerce DateSaturday, October 31, 2020

Trademark Owner History

Party NameSyncromune, Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressFort Lauderdale, FL 33308
Party NameSyncromune, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressFort Lauderdale, FL 33308
Party NameSyncromune, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressFort Lauderdale, FL 33339

Trademark Events

Event DateEvent Description
Friday, January 28, 2022NEW APPLICATION ENTERED
Monday, January 31, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, November 3, 2022ASSIGNED TO EXAMINER
Thursday, November 3, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, November 16, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, December 6, 2022PUBLISHED FOR OPPOSITION
Tuesday, December 6, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, January 31, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, July 19, 2023DIVISIONAL REQUEST RECEIVED
Wednesday, July 19, 2023TEAS REQUEST TO DIVIDE RECEIVED
Tuesday, July 25, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, July 25, 2023SOU EXTENSION 1 FILED
Thursday, August 3, 2023CASE ASSIGNED TO INTENT TO USE PARALEGAL
Thursday, August 3, 2023SOU EXTENSION 1 GRANTED
Friday, August 4, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, January 25, 2024SOU EXTENSION 2 FILED
Thursday, January 25, 2024SOU EXTENSION 2 GRANTED
Saturday, January 27, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, February 1, 2024DIVISIONAL PROCESSING COMPLETE
Thursday, February 1, 2024NOTICE OF ALLOWANCE CANCELLED
Thursday, February 1, 20241(B) BASIS DELETED; PROCEED TO REGISTRATION
Tuesday, March 12, 2024REGISTERED-PRINCIPAL REGISTER
Tuesday, March 12, 2024NOTICE OF REGISTRATION CONFIRMATION EMAILED

Related Keywords

syncrovax development technology delivery therapeutics drugs drug